Johnson & Johnson’s multiple myeloma treatment secures EC approval

The EC has approved an extended use of Johnson & Johnson's Tecvayli, along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).

The post Johnson & Johnson’s multiple myeloma treatment secures EC approval appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.